LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence.

LGLL bone marrow failure syndromes clonality cytopenias large granular lymphocytes

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
25 Oct 2022
Historique:
received: 15 09 2022
revised: 17 10 2022
accepted: 21 10 2022
entrez: 11 11 2022
pubmed: 12 11 2022
medline: 12 11 2022
Statut: epublish

Résumé

Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed, precisely assigning whether cytopenias might be related to inadequate hematopoiesis (i.e., LGL as a marginal finding) rather than immune-mediated mechanisms (i.e., LGLL) is far from being an easy task. As LGL clones acquire different pathogenetic roles and relevance according to their diverse clinical settings, their detection in the landscape of bone marrow failures and myeloid neoplasms has recently raised growing clinical interest. In this regard, the current availability of different diagnostic techniques, including next generation sequencing, shed light on the relationship between LGL clones and cytopenias, paving the way towards a better disease classification for precision medicine treatments. Herein, we discuss the clinical relevance of LGL clones in the diagnostic algorithm to be followed in patients presenting with cytopenias, offering a foundation for rational management approaches.

Identifiants

pubmed: 36358655
pii: cancers14215236
doi: 10.3390/cancers14215236
pmc: PMC9655579
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Am Soc Clin Oncol Educ Book. 2018 May 23;38:616-625
pubmed: 30231346
Am J Surg Pathol. 2005 Jul;29(7):935-41
pubmed: 15958859
Blood. 2011 Oct 20;118(16):4384-93
pubmed: 21865345
J Pediatr Hematol Oncol. 2019 Nov;41(8):e542-e545
pubmed: 30188351
Oncotarget. 2015 Dec 15;6(40):42938-51
pubmed: 26556869
Transplant Proc. 2020 Jun;52(5):1617-1618
pubmed: 32505499
Haematologica. 2020 May;105(5):1351-1360
pubmed: 31467122
Am J Cancer Res. 2021 Apr 15;11(4):1616-1631
pubmed: 33948377
Hum Pathol. 2000 Oct;31(10):1266-73
pubmed: 11070120
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Blood. 2013 Oct 3;122(14):2453-9
pubmed: 23926297
Clin Lymphoma Myeloma. 2009;9 Suppl 3:S244-53
pubmed: 19778848
Hematology Am Soc Hematol Educ Program. 2012;2012:652-9
pubmed: 23233648
Am J Clin Pathol. 2021 Oct 13;156(5):829-838
pubmed: 33929502
Life Sci. 2017 Nov 15;189:71-75
pubmed: 28935248
Front Immunol. 2022 May 03;13:869570
pubmed: 35592317
Leukemia. 2020 Mar;34(3):957-962
pubmed: 31624375
Expert Rev Hematol. 2011 Jun;4(3):317-28
pubmed: 21668396
Front Immunol. 2022 Jan 04;12:790455
pubmed: 35058929
Front Pediatr. 2018 Oct 10;6:292
pubmed: 30364049
Am J Hematol. 2021 Jul 1;96(7):772-780
pubmed: 33819354
Cancers (Basel). 2021 Sep 01;13(17):
pubmed: 34503230
Blood. 2022 Sep 12;:
pubmed: 36096473
Blood Cancer J. 2022 Feb 24;12(2):31
pubmed: 35210405
Blood Rev. 2006 Sep;20(5):245-66
pubmed: 16530306
Cancer. 1987 Dec 15;60(12):2971-8
pubmed: 3677021
Nat Commun. 2022 Apr 11;13(1):1981
pubmed: 35411050
N Engl J Med. 2020 Dec 24;383(26):2590
pubmed: 33369363
Leukemia. 2022 Nov;36(11):2551-2557
pubmed: 36109593
Blood Cancer J. 2022 Feb 22;12(2):30
pubmed: 35194022
J Immunol. 2013 Oct 1;191(7):3578-93
pubmed: 24014875
Leukemia. 2020 Apr;34(4):1116-1124
pubmed: 31740810
Cancers (Basel). 2021 Aug 02;13(15):
pubmed: 34359799
Blood. 2021 Apr 15;137(15):2001-2009
pubmed: 33657207
Blood Cancer J. 2018 Jun 5;8(6):51
pubmed: 29891951
Blood. 2021 May 6;137(18):2450-2462
pubmed: 33512449
Blood. 2022 May 19;139(20):3002-3004
pubmed: 35587872
Int J Lab Hematol. 2018 May;40 Suppl 1:97-103
pubmed: 29741263
N Engl J Med. 2012 May 17;366(20):1905-13
pubmed: 22591296
Am J Pathol. 2001 Nov;159(5):1861-8
pubmed: 11696446
Am J Hematol. 2017 Jan;92(1):E6-E8
pubmed: 27761930
Semin Hematol. 2003 Jul;40(3):201-12
pubmed: 12876669
Front Immunol. 2022 Sep 02;13:935321
pubmed: 36119097
Cancers (Basel). 2021 Jan 03;13(1):
pubmed: 33401595
Front Immunol. 2019 Nov 29;10:2735
pubmed: 31849946
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):181-186
pubmed: 29222254
Am Soc Clin Oncol Educ Book. 2019 Jan;39:400-410
pubmed: 31099654
Am J Pathol. 2003 Aug;163(2):763-71
pubmed: 12875995
Blood. 2017 Mar 2;129(9):1082-1094
pubmed: 28115367
Front Oncol. 2022 Jan 05;11:775313
pubmed: 35070980
Curr Opin Hematol. 2009 Jan;16(1):27-34
pubmed: 19057202
Leukemia. 2022 Jul;36(7):1947-1950
pubmed: 35597805
Blood Rev. 2014 May;28(3):87-94
pubmed: 24679833
Oncotarget. 2017 Jun 27;8(37):61876-61889
pubmed: 28977911
Front Oncol. 2022 May 13;12:869205
pubmed: 35646651
Leuk Res. 2008 May;32(5):823-7
pubmed: 17915315
Leuk Lymphoma. 1996 Oct;23(3-4):405-8
pubmed: 9031124
Leukemia. 2013 Oct;27(10):1981-7
pubmed: 23765225
Nat Commun. 2022 Jun 8;13(1):3298
pubmed: 35676278
Curr Hematol Malig Rep. 2020 Apr;15(2):103-112
pubmed: 32062772
Leuk Res. 2012 May;36(5):581-7
pubmed: 22386729
J Clin Immunol. 2021 Aug;41(6):1250-1265
pubmed: 33876323
Front Oncol. 2020 Feb 18;10:152
pubmed: 32133291
Int J Lab Hematol. 2022 Feb;44(1):27-28
pubmed: 34562064
Nat Genet. 2022 May;54(5):637-648
pubmed: 35513723
Leukemia. 2019 Oct;33(10):2495-2505
pubmed: 30940907
Cancer Sci. 2012 Jun;103(6):1079-83
pubmed: 22360679
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Pediatr Blood Cancer. 2008 Jan;50(1):142-5
pubmed: 16767728
Histopathology. 2007 Apr;50(5):547-54
pubmed: 17394489
J Allergy Clin Immunol. 2019 Apr;143(4):1482-1495
pubmed: 30170123
Leukemia. 2021 Jun;35(6):1792-1796
pubmed: 33414481
Blood. 2002 Jan 1;99(1):268-74
pubmed: 11756181
Best Pract Res Clin Haematol. 2019 Sep;32(3):207-216
pubmed: 31585621
Blood Cells Mol Dis. 2021 Mar;87:102528
pubmed: 33341510
Blood. 1994 Sep 1;84(5):1620-7
pubmed: 8068951
Blood. 2021 Jun 10;137(23):3237-3250
pubmed: 33512451
Front Oncol. 2021 Oct 01;11:748610
pubmed: 34660312
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):418-427
pubmed: 34889424
Leuk Lymphoma. 2018 Feb;59(2):416-422
pubmed: 28633612
Haematologica. 2010 Sep;95(9):1534-41
pubmed: 20378561
Cells. 2021 Oct 19;10(10):
pubmed: 34685780
Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):400-5
pubmed: 22999943
Blood. 2013 Dec 12;122(25):4077-85
pubmed: 24149287
Blood. 2013 May 30;121(22):4541-50
pubmed: 23596048
Blood Cancer J. 2020 Apr 22;10(4):42
pubmed: 32321919
Mod Pathol. 2020 Oct;33(10):2046-2057
pubmed: 32404954
N Engl J Med. 2015 Jul 2;373(1):35-47
pubmed: 26132940
J Clin Oncol. 2022 Sep 2;:JCO2200710
pubmed: 36054881
Front Oncol. 2022 Mar 10;12:849917
pubmed: 35359386
Curr Opin Hematol. 2011 Jul;18(4):254-9
pubmed: 21546829
Hematology. 2019 Dec;24(1):139-147
pubmed: 30334691
Haematologica. 2009 Aug;94(8):1066-74
pubmed: 19546439
Leukemia. 2020 Nov;34(11):3097-3099
pubmed: 32565544
Blood. 2003 Sep 1;102(5):1797-805
pubmed: 12750175
Am J Hematol. 2002 Feb;69(2):132-4
pubmed: 11835350
Cancers (Basel). 2022 Jan 14;14(2):
pubmed: 35053571

Auteurs

Giulia Calabretto (G)

Department of Medicine, Padua University School of Medicine, Hematology Division, 35129 Padua, Italy.
Veneto Institute of Molecular Medicine (VIMM), 35129 Padua, Italy.

Enrico Attardi (E)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.

Carmelo Gurnari (C)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44106, USA.

Gianpietro Semenzato (G)

Department of Medicine, Padua University School of Medicine, Hematology Division, 35129 Padua, Italy.
Veneto Institute of Molecular Medicine (VIMM), 35129 Padua, Italy.

Maria Teresa Voso (MT)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.

Renato Zambello (R)

Department of Medicine, Padua University School of Medicine, Hematology Division, 35129 Padua, Italy.
Veneto Institute of Molecular Medicine (VIMM), 35129 Padua, Italy.

Classifications MeSH